Treatment of the inflammatory myopathies: update and practical recommendations.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656560902913815 PMID 19405792
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis

  2008cited by this paper
• Treatment of refractory juvenile dermatomyositis with tacrolimus

  2008cited by this paper
• Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus

  2008cited by this paper
• Open-Label Trial of Anti-TNF-α in Dermato- and Polymyositis Treated Concomitantly with Methotrexate

  2008cited by this paper
• A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies

  2008cited by this paper
• Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis.

  2008cited by this paper
• Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis.

  2008cited by this paper
• Mycophenolate mofetil treatment in resistant myositis.

  2007cited by this paper
• Spontaneous recovery of dermatomyositis and unspecified myositis in three adult patients

  2007cited by this paper
• A pilot trial of rituximab in the treatment of patients with dermatomyositis.

  2007cited by this paper
• Advances in the immunopathophysiology of the idiopathic inflammatory myopathies: Not as simple as suspected

  2007cited by this paper
• Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial.

  2007cited by this paper
• Rituximab for refractory polymyositis: an open-label prospective study.

  2007cited by this paper
• Treatment of inclusion body myositis with cyclosporin-A or tacrolimus: successful long-term management in patients with earlier active disease and concomitant autoimmune features.

  2007cited by this paper
• A Local Antigen-Driven Humoral Response Is Present in the Inflammatory Myopathies1

  2007cited by this paper
• Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis.

  2007cited by this paper
• Mycophenolate mofetil in dermatomyositis: Is it safe?

  2006cited by this paper
• The heart in dermatomyositis and polymyositis.

  2006cited by this paper
• Use of etanercept in the treatment of dermatomyositis: a case series.

  2006cited by this paper
• Long-term outcome in polymyositis and dermatomyositis

  2006cited by this paper
• [Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases].

  2006cited by this paper
• Pilot trial of etanercept in the treatment of inclusion-body myositis

  2006cited by this paper
• Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging

  2006cited by this paper
• Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis.

  2005cited by this paper
• Plasma cells in muscle in inclusion body myositis and polymyositis

  2005cited by this paper
• Successful treatment of rapidly progressive interstitial pneumonia with autologous peripheral blood stem cell transplantation in a patient with dermatomyositis

  2005cited by this paper
• Interstitial lung disease in polymyositis and dermatomyositis

  2005cited by this paper
• Rituximab in the treatment of dermatomyositis: an open-label pilot study.

  2005cited by this paper
• Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.

  2005cited by this paper
• Treatment of antisynthetase-associated interstitial lung disease with tacrolimus.

  2005cited by this paper
• Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis.

  2005cited by this paper
• Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis

  2004cited by this paper
• 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands.

  2004cited by this paper
• Tacrolimus-associated myositis: a case report in a renal transplant patient.

  2004cited by this paper
• The effect of physical exercise following acute disease exacerbation in patients with dermato/polymyositis

  2003cited by this paper
• Polymyositis

  2003cited by this paper
• Anti–T-lymphocyte globulin treatment in inclusion body myositis

  2003cited by this paper
• Unicorns, dragons, polymyositis, and other mythological beasts

  2003cited by this paper
• Molecular profiles of inflammatory myopathies

  2002cited by this paper
• Relation between dermatomyositis and polymyositis and cancer.

  2001cited by this paper
• Anti-Jo-1 positive inclusion body myositis with a marked and sustained clinical improvement after oral prednisone

  2001cited by this paper
• A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM

  2001cited by this paper
• Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis.

  2000cited by this paper
• Oral pulsed high-dose dexamethasone for myositis

  2000cited by this paper
• Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens.

  1998cited by this paper
• HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies.

  1998cited by this paper
• Treatment of inclusion-body myositis with IVIg

  1997cited by this paper
• Inclusion body myositis: Clinical and pathological boundaries

  1996cited by this paper
• Inclusion body myositis

  1995cited by this paper
• Classification criteria for polymyositis and dermatomyositis.

  1995cited by this paper
• Inclusion body myositis

  1994cited by this paper
• Treatment of inclusion‐body myositis with high‐dose intravenous immunoglobulin

  1993cited by this paper
• A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.

  1993cited by this paper
• Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis.

  1992cited by this paper
• Polymyositis, dermatomyositis and inclusion-body myositis.

  1991cited by this paper
• ECG abnormalities in polymyositis.

  1984cited by this paper
• Azathioprine with prednisone for polymyositis. A controlled, clinical trial.

  1980cited by this paper
• Cardiac involvement in polymyositis.

  1978cited by this paper
• Polymyositis and dermatomyositis (second of two parts).

  1975cited by this paper
• Polymyositis and dermatomyositis (first of two parts).

  1975cited by this paper

• Recruitment rate comparison between a virtual tele-research cohort and a traditional center-based cohort in idiopathic inflammatory myopathy.

  2025cites this paper
• Diagnosis of Thyroid Neoplasm-Associated Dermatomyositis in Ethiopian Woman

  2024cites this paper
• Reliability, Validity and Responsiveness of Physical Activity Monitors in Patients with Inflammatory Myopathy.

  2021cites this paper
• Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines

  2019cites this paper
• Dermatomyositis: An Acute Flare and Current Treatments

  2019cites this paper
• Physical therapy in adult inflammatory myopathy patients: a systematic review

  2019cites this paper
• Muscle Strength and Muscle Endurance During the First Year of Treatment of Polymyositis and Dermatomyositis: A Prospective Study

  2018cites this paper
• Effect of endurance exercise on microRNAs in myositis skeletal muscle—A randomized controlled study

  2017cites this paper
• Inflammatory Myopathies with Cutaneous Involvement: from Diagnosis to Therapy

  2017cites this paper
• Acute heart failure and rhabdomyolysis: a clue for the diagnosis of polymyositis with cardiac involvement.

  2017cites this paper
• Long-term efficacy of intravenous immunoglobulin in a case of polymyositis with limited application of steroid therapy

  2017cites this paper
• Betekintés az idiopathiás inflammatorikus myopathiában szenvedő betegek gyógytornájába Insight into the training of patients with idiopathic inflammatory myopathy

  2016cites this paper
• [Insight into the training of patients with idiopathic inflammatory myopathy].

  2016cites this paper
• Endurance Exercise Improves Molecular Pathways of Aerobic Metabolism in Patients With Myositis

  2016cites this paper
• Patients’ Experience of Myositis and Further Validation of a Myositis-specific Patient Reported Outcome Measure — Establishing Core Domains and Expanding Patient Input on Clinical Assessment in Myositis. Report from OMERACT 12

  2015cites this paper
• New Insights into the Benefits of Exercise for Muscle Health in Patients with Idiopathic Inflammatory Myositis

  2014cites this paper
• Safety and possible effects of low-intensity resistance training associated with partial blood flow restriction in polymyositis and dermatomyositis

  2014cites this paper
• Hand function, activity limitation, and health-related quality of life in patients with polymyositis and dermatomyositis

  2014cites this paper
• Resistive Home Exercise in Patients with Recent-onset Polymyositis and Dermatomyositis — A Randomized Controlled Single-blinded Study with a 2-year Followup

  2014cites this paper
• Autoantibodies to cytosolic 5′‐nucleotidase 1A in inclusion body myositis

  2013cites this paper
• Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis

  2013cites this paper
• Targeted immunotherapy trials for idiopathic inflammatory myopathies

  2013cites this paper
• Update on Treatment of Inclusion Body Myositis

  2013cites this paper
• Current Essentials in Inflammatory Myopathies

  2013cites this paper
• Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review

  2013cites this paper
• Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies.

  2013cites this paper
• Schwere Dysphagie und flammende Hautrötung bei einem 59-jährigen Patienten

  2013cites this paper
• Improvement in Health and Possible Reduction in Disease Activity Using Endurance Exercise in Patients With Established Polymyositis and Dermatomyositis: A Multicenter Randomized Controlled Trial With a 1‐Year Open Extension Followup

  2013cites this paper
• Nuevos conceptos en el síndrome por anticuerpos antisintetasa

  2013cites this paper
• Polymyositis, dermatomyositis and inclusion body myositis

  2012cites this paper
• Rituximab restored the muscle power and rescued from a refractory fatal respiratory failure in a patient with elderly-onset polymyositis.

  2012cites this paper
• The Myositis Activities Profile — Initial Validation for Assessment of Polymyositis/Dermatomyositis in the USA

  2012cites this paper
• Exercise in Inflammatory Myopathies, Including Inclusion Body Myositis

  2012cites this paper
• Medical costs and health‐care resource use in patients with inflammatory myopathies in an insured population

  2012cites this paper
• Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan

  2012cites this paper
• Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis

  2012cites this paper
• Idiopathic inflammatory myopathies: definition and management of refractory disease.

  2011cites this paper
• Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.

  2011cites this paper
• Rituximab treatment in patients with refractory inflammatory myopathies.

  2011cites this paper
• [Association of anti synthetase syndrome and limited systemic sclerosis in a patient: successful treatment with rituximab].

  2011cites this paper
• Use of methotrexate in inflammatory myopathies.

  2010cites this paper
• Long-term efficacy of intravenously administered immunoglobulin in a case of polymyositis with limited application of steroid therapy

  2010cites this paper
• Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls

  2010cites this paper
• Clinical and pathophysiological significance of myositis-specific and myositis-associated autoantibodies

  2010cites this paper
• Mycophenolate mofetil: A possible therapeutic agent for children with juvenile dermatomyositis

  2010cites this paper
• The treatment of polymyositis, dermatomyositis and inclusion body myositis

  2010cites this paper
• [Dermatomyositis].

  2009cites this paper